Tirzepatide as monotherapy improved markers of beta-cell function and insulin sensitivity in type 2 diabetes (SURPASS-1)

Tirzepatide is a GIP and GLP-1 receptor agonist approved for treatment of type 2 diabetes (T2D). SURPASS-1, a Phase 3 trial of tirzepatide monotherapy in people with early T2D, enables evaluating effects of tirzepatide on pancreatic beta-cell function and insulin sensitivity (IS) without other background antihyperglycemic medications. This post-hoc analysis explored changes in biomarkers of beta-cell function and IS with tirzepatide monotherapy.